What Is SS-31?
SS-31 (Elamipretide) is a first-in-class mitochondria-targeting peptide developed to address the root cause of diseases driven by mitochondrial dysfunction. It is a tetrapeptide, a chain of just four amino acids, with a unique structure that allows it to selectively accumulate within mitochondria rather than distributing broadly throughout the cell.
The compound was created with a specific molecular rationale: cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, plays a structural role in organizing the electron transport chain complexes that generate ATP. In aging, disease, and ischemic injury, cardiolipin becomes oxidized and peroxidized, destabilizing these complexes and impairing energy production. SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, preventing its oxidation and preserving the architecture of the electron transport chain.
This mechanism distinguishes SS-31 from both conventional antioxidants (which scavenge free radicals after they are produced) and most peptides in the biohacking space (which act through growth factor or hormonal pathways). SS-31 operates at the level of cellular bioenergetics, making it particularly relevant for conditions where mitochondrial failure is a primary driver of pathology.How It Works
Cardiolipin Stabilization
The central mechanism of SS-31 is its interaction with cardiolipin in the inner mitochondrial membrane. Cardiolipin serves as a scaffold for the protein complexes of the electron transport chain (Complexes I, III, and IV), holding them in the optimal spatial arrangement for efficient electron transfer. When cardiolipin is damaged by reactive oxygen species, these complexes dissociate and electron transfer becomes inefficient, generating more reactive oxygen species in a destructive feedback loop.
SS-31 binds cardiolipin through a combination of electrostatic attraction (its cationic charge is drawn to cardiolipin's anionic head groups) and hydrophobic insertion (its aromatic residues embed in the lipid bilayer). This stabilization prevents cardiolipin peroxidation and maintains the structural integrity of the electron transport chain.
Electron Transport Chain Optimization
By preserving cardiolipin and the supramolecular organization of electron transport chain complexes, SS-31 optimizes electron flow through Complexes I, III, and IV. This improved electron transfer efficiency has two consequences: increased ATP production and reduced superoxide radical generation. In dysfunctional mitochondria, studies have demonstrated that SS-31 can improve ATP production by 30–60%, while simultaneously reducing harmful reactive oxygen species that would otherwise damage cellular components.
Mitochondrial Dynamics and Biogenesis
Evidence from preclinical studies suggests SS-31 also activates PGC-1α signaling pathways, a master regulator of mitochondrial biogenesis. Activation of this pathway promotes mitochondrial fusion and the generation of new mitochondria, contributing to improvements in overall mitochondrial mass and function over extended treatment periods. This biogenesis effect may explain why some structural and functional benefits continue to develop over months of treatment.
Anti-Inflammatory Effects
Mitochondrial reactive oxygen species are potent activators of the NLRP3 inflammasome, a multiprotein complex that drives inflammatory cytokine production. By reducing mitochondrial reactive oxygen species generation, SS-31 reduces NLRP3 inflammasome activation and the subsequent release of pro-inflammatory cytokines including IL-1β and IL-18. This anti-inflammatory effect has been observed across multiple tissue types in preclinical research and may contribute to the compound's protective effects in cardiac and renal injury models.